Literature DB >> 33811570

Minimally invasive versus conventional continuous-flow left ventricular assist device implantation for heart failure: a meta-analysis.

Bufan Zhang1, Shaohua Guo2, Zean Fu1, Zhigang Liu3.   

Abstract

Many studies have reported various minimally invasive techniques for continuous-flow left ventricular assist device implantation. There is no consensus on whether minimally invasive techniques can bring more benefits for patients compared with the conventional technique, due to the limited number of patients and diverse results in current studies. Our meta-analysis mainly discussed the comparison of minimally invasive and conventional techniques. We searched controlled trials from PubMed, Cochrane Library, and Embase databases until Dec 11, 2020. Perioperative and postoperative outcomes were analyzed among 10 included studies. The protocol has been registered with PROSPERO (CRD42020221532). There were no statistical differences in the 30-day mortality (OR 0.57; 95% CI 0.29 to 1.14), 6-month mortality (OR 0.66; 95% CI 0.41 to 1.05), neurological dysfunction (OR 1.10; 95% CI 0.69 to 1.76), major infection (OR 0.68; 95% CI 0.36 to 1.28), and pump thrombus (OR 1.49; 95% CI 0.63 to 3.52) among the cohorts. Minimally invasive techniques were associated with lower incidences of major bleeding (OR 0.39; 95% CI 0.22 to 0.68), severe right heart failure (OR 0.43; 95% CI 0.23 to 0.81), and less blood-product utilization (SMD -0.44). Sensitivity analysis suggested that minimally invasive techniques were associated with a lower incidence of respiratory failure (OR 0.50; 95% CI 0.26 to 0.96) and shorter mechanical ventilation time (SMD -0.53). Subgroup analysis demonstrated that patients, implanted with a centrifugal pump by minimally invasive techniques, were associated with a shorter length of intensive care unit (ICU) stay (SMD -0.27) and hospital stay (SMD -0.42), and less blood-product utilization (SMD -0.26). In conclusion, minimally invasive techniques can reduce the risks of major bleeding, severe right heart failure, and blood-product utilization, as well as have positive impacts on reducing mechanical ventilation time and the risk of respiratory failure. Minimally invasive centrifugal pump implantation can reduce the length of ICU and hospital stay.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Continuous-flow left ventricular assist device; Heart failure; Minimally invasive techniques; The conventional technique

Mesh:

Year:  2021        PMID: 33811570     DOI: 10.1007/s10741-021-10102-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  26 in total

Review 1.  Minimally invasive is the future of left ventricular assist device implantation.

Authors:  George Makdisi; I-Wen Wang
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Minimally invasive thoratec Heartmate II implantation in the setting of severe thoracic aortic calcification.

Authors:  Julia Riebandt; Sigrid Sandner; Stephane Mahr; Thomas Haberl; Angela Rajek; Guenther Laufer; Heinrich Schima; Daniel Zimpfer
Journal:  Ann Thorac Surg       Date:  2013-09       Impact factor: 4.330

3.  Outcomes of midterm circulatory support by left ventricular assist device implantation with descending aortic anastomosis.

Authors:  Kan Nawata; Takashi Nishimura; Shunei Kyo; Motoyuki Hisagi; Osamu Kinoshita; Aya Saito; Noboru Motomura; Shinichi Takamoto; Minoru Ono
Journal:  J Artif Organs       Date:  2010-10-30       Impact factor: 1.731

4.  In-hospital outcomes of a minimally invasive off-pump left thoracotomy approach using a centrifugal continuous-flow left ventricular assist device.

Authors:  Bantayehu Sileshi; Nicholas A Haglund; Mary E Davis; Nicole M Tricarico; John M Stulak; Zain Khalpey; Matthew R Danter; Robert Deegan; Jason Kennedy; Mary E Keebler; Simon Maltais
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

Review 5.  Different surgical strategies for implantation of continuous-flow VADs-Experience from Deutsches Herzzentrum Berlin.

Authors:  Thomas Krabatsch; Thorsten Drews; Evgenij Potapov; Yugo Weng; Miralem Pasic; Roland Hetzer
Journal:  Ann Cardiothorac Surg       Date:  2014-09

Review 6.  Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.

Authors:  James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel
Journal:  J Heart Lung Transplant       Date:  2017-07-15       Impact factor: 10.247

Review 7.  Ventricular Assist Devices - Evolution of Surgical Heart Failure Treatment.

Authors:  Dominik Wiedemann; Thomas Haberl; Julia Riebandt; Paul Simon; Günther Laufer; Daniel Zimpfer
Journal:  Eur Cardiol       Date:  2014-07

8.  The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships.

Authors:  Robert L Kormos; Jennifer Cowger; Francis D Pagani; Jeffrey J Teuteberg; Daniel J Goldstein; Jeffrey P Jacobs; Robert S Higgins; Lynne W Stevenson; Josef Stehlik; Pavan Atluri; Kathleen L Grady; James K Kirklin
Journal:  J Heart Lung Transplant       Date:  2019-02       Impact factor: 10.247

9.  Left ventricular assist device outflow graft: alternative sites.

Authors:  Magdy M El-Sayed Ahmed; Muhammad Aftab; Steve K Singh; Hari R Mallidi; Oscar H Frazier
Journal:  Ann Cardiothorac Surg       Date:  2014-09

10.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.

Authors:  Xiang Wan; Wenqian Wang; Jiming Liu; Tiejun Tong
Journal:  BMC Med Res Methodol       Date:  2014-12-19       Impact factor: 4.615

View more
  1 in total

1.  Minimally invasive apical cannulation and cannula design for short-term mechanical circulatory support devices.

Authors:  Marcell Székely; Tamás Ruttkay; Ferenc Imre Suhai; Áron Bóna; Béla Merkely; László Székely
Journal:  BMC Cardiovasc Disord       Date:  2022-09-04       Impact factor: 2.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.